VectorGlobal IAG Inc. Purchases Shares of 4,245 Astrazeneca Plc $AZN

VectorGlobal IAG Inc. acquired a new stake in shares of Astrazeneca Plc (NYSE:AZN) in the 1st quarter, Holdings Channel.com reports. The institutional investor acquired 4,245 shares of the company’s stock, valued at approximately $822,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Triumph Capital Management purchased a new position in shares of Astrazeneca in the 3rd quarter worth $25,000. MV Capital Management Inc. purchased a new stake in Astrazeneca during the fourth quarter valued at about $26,000. Mascoma Wealth Management LLC purchased a new stake in Astrazeneca during the first quarter valued at about $26,000. Eagle Bay Advisors LLC acquired a new stake in Astrazeneca during the fourth quarter worth about $30,000. Finally, YANKCOM Partnership acquired a new stake in Astrazeneca during the fourth quarter worth about $31,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Astrazeneca News Summary

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: A combination with Bristol Myers Squibb could create a pharmaceutical company valued at approximately $400 billion, potentially ranking among the world’s largest drugmakers and providing greater scale, a broader product portfolio and possible cost synergies. AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal
• Neutral Sentiment: The Financial Times reports that the companies have explored a deal in recent months, citing people familiar with the matter. The discussions may not result in a transaction, leaving the timing, structure and valuation uncertain. AstraZeneca holds talks with Bristol Myers Squibb on potential megadeal
• Negative Sentiment: Investors appear concerned that AstraZeneca could need to pay a substantial premium, assume additional debt or issue shares to fund such a large transaction. Regulatory scrutiny, integration challenges and execution risks could also weigh on the stock. Reports indicated a potential one-day decline of about 7%, which would be the company’s steepest since the 2024 U.S. presidential election. AstraZeneca shares drop after report on merger talks
• Negative Sentiment: Separately, AstraZeneca has seen a significant increase in short interest, indicating greater bearish positioning and potentially adding pressure to the shares. AstraZeneca sees significant increase in short interest

Astrazeneca Price Performance

Shares of NYSE AZN opened at $169.77 on Monday. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.89 and a quick ratio of 0.67. Astrazeneca Plc has a 1-year low of $145.79 and a 1-year high of $212.71. The company has a market capitalization of $263.30 billion, a price-to-earnings ratio of 25.38, a PEG ratio of 1.47 and a beta of 0.26. The business has a 50-day moving average of $179.02 and a 200-day moving average of $187.83.

Astrazeneca (NYSE:AZN) last announced its earnings results on Monday, July 27th. The company reported $2.63 EPS for the quarter, beating the consensus estimate of $2.50 by $0.13. The business had revenue of $15.38 billion for the quarter, compared to the consensus estimate of $15.44 billion. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.The company’s revenue was up 6.4% on a year-over-year basis. During the same period last year, the business posted $2.17 EPS. On average, equities analysts anticipate that Astrazeneca Plc will post 10.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on AZN. DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. HSBC downgraded shares of Astrazeneca from a “buy” rating to a “hold” rating in a research report on Monday, July 13th. Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Finally, Barclays reiterated a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Twelve investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Astrazeneca presently has an average rating of “Moderate Buy” and an average price target of $211.00.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.